化学
泛素连接酶
Bcl xL型
蛋白质水解
细胞凋亡
作用机理
癌症研究
泛素
程序性细胞死亡
药理学
生物化学
体外
生物
酶
基因
作者
Pratik Pal,Dinesh Thummuri,Dongwen Lv,Xingui Liu,Peiyi Zhang,Wanyi Hu,Saikat Kumar Poddar,Nan Hua,Sajid Khan,Yaxia Yuan,Xuan Zhang,Daohong Zhou,Guangrong Zheng
标识
DOI:10.1021/acs.jmedchem.1c00517
摘要
BCL-XL and BCL-2 are important targets for cancer treatment. BCL-XL specific proteolysis-targeting chimeras (PROTACs) have been developed to circumvent the on-target platelet toxicity associated with BCL-XL inhibition. However, they have minimal effects on cancer cells that are dependent on BCL-2 or both BCL-XL and BCL-2. Here we report a new series of BCL-PROTACs. The lead PZ703b exhibits high potency in inducing BCL-XL degradation and in inhibiting but not degrading BCL-2, showing a hybrid dual-targeting mechanism of action that is unprecedented in a PROTAC molecule. As a result, PZ703b is highly potent in killing BCL-XL dependent, BCL-2 dependent, and BCL-XL/BCL-2 dual-dependent cells in an E3 ligase (VHL)-dependent fashion. We further found that PZ703b forms stable {BCL-2:PROTAC:VCB} ternary complexes in live cells that likely contribute to the enhanced BCL-2 inhibition by PZ703b. With further optimization, analogues of PZ703b could potentially be developed as effective antitumor agents by co-targeting BCL-XL and BCL-2.
科研通智能强力驱动
Strongly Powered by AbleSci AI